Revolade 50mg is the indicated for the treatment of patients having Severe aplastic Anemia.Buy Revolade 50mg tablets @ MHP – PowerPoint PPT presentation
Eltrombopag is sold under the brand name Revolade 50 mg and it is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body.
3 (No Transcript) 4 DESCRIPTION
Revolade 50mg can reduces the risk of bleeding by increasing platelets in your blood.Revolade 50mg tablet which is used asprescription drug under the guidance of the medical practioners
5 INDICATION
Revolade 50mg is an anticancer medication which isIndicated for the treatment of patients having Severe aplastic Anemia First line treatment of severe aplastic Anemia Treatment of refractory severe aplastic Anemia
6 (No Transcript) 7
Indicated for the treatment to stimulate the growth and development of platelets in the bone marrowPrimarily indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection
8 MECHANISM OF ACTION
Eltrombopag consist of class of drugs known as thrombopoietin (TPO) receptor agonists. A class of drugs is a group of medications which work in a same way.Eltrombopag mechanism by raising cells in your bone marrow and causes these cells to make more platelets. This effect reduces your risk of bleeding.
9 PROPERTIES 10 PROPERTIES
Ingredients Eltrombopag
Strength 50mg
Package 7 tablets in a strip
11 ADME
AbsorptionHigh plasma concentration is 2-6 hours
DistributionMaximum human plasma protein bounding is gt99 and in blood plasma level is 50 to 79
12 ADME
Metabolismgenerally metabolised via cleavage, oxidation and conjugation with glucuronic acid.
EliminationRevolade 50mg eliminated mainly via feces 59, along with 31 via renally excretedRevolade 50mg Half-life for healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours
13 DOSAGE MANAGEMENT
The usual dose for Chronic Hepatitis C-associated Thrombocytopenia is 25 mg PO qDay. Dose is managed in 25 mg accretion q2weeks PRN to attain target Plt needed to start/control antiviral therapy with pegylated interferon and ribavirin not to exceed 100 mg/day
14 (No Transcript) 15 Severe Aplastic Anemia
First-line therapy When combination with standard immunosuppressive treatment, for patients with serious aplastic Anemia (SAA) The usual dose for severe Aplastic Anemia 150 mg PO qDay for 6 months Avoid taking of more than starting dose total duration is 6 months
16
Refractory SAA In this condition the drug given who fail to respond enough to at least 1 before immunosuppressive therapy The usual dose for Refractory SAA 50 mg PO qDay The recommended dose for Chronic Immune Thrombocytopenia is 50 mg PO qDay Adjust dose to manage and control platelet count (Plt) gt50 x 109/L to reduce the risk of bleeding not to exceed 75 mg/day
17 PRECAUTIONS
The drug Revolade 50mg may have high risk of severe and probably life-threatening hepatotoxicity monitor liver function before and during treatment
While receiving the drug, if patient with hepatic impairment (Child-Pugh Class A, B, C) initiates therapy for first- line treatment of severe aplastic Anemia, reduce initial dose
18 (No Transcript) 19 PRECAUTIONS
When treatment, If the patients have cataracts, do not use the drug due to the Revolade 50mg effects cataracts and make the condition worse.
Avoid the Revolade 50mg while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.
20 PRECAUTIONS
While on treatment with drug Revolade then Portal vein thrombosis reported in patients with chronic liver disease.
21 SIDE EFFECTS
Common side effects of Revolade 50mg Headache Cough Loss of appetite Flu Reduced red blood cells Diarrhoea Nausea Fever Weakness
22 SIDE EFFECTS
Serious side effects of Revolade 50mg Swelling of legs Abdomen swelling Confusion Chest pain Dyspnea Cloudy vision Urine in dark colour Yellowing of your skin Sensitivity to light Seeing circles around lights
23 (No Transcript) 24
PREGNANCY
Pregnancy category is C Safety of drug during pregnancy is not established
LACTATION
During breast feeding, avoid using of drug Revolade